Search results for " Leukemia"

showing 10 items of 666 documents

Hematopoietic stem-cell transplantation for advanced systemic mastocytosis

2014

Purpose Advanced systemic mastocytosis (SM), a fatal hematopoietic malignancy characterized by drug resistance, has no standard therapy. The effectiveness of allogeneic hematopoietic stem-cell transplantation (alloHCT) in SM remains unknown. Patients and Methods In a global effort to define the value of HCT in SM, 57 patients with the following subtypes of SM were evaluated: SM associated with clonal hematologic non–mast cell disorders (SM-AHNMD; n = 38), mast cell leukemia (MCL; n = 12), and aggressive SM (ASM; n = 7). Median age of patients was 46 years (range, 11 to 67 years). Donors were HLA-identical (n = 34), unrelated (n = 17), umbilical cord blood (n = 2), HLA-haploidentical (n = 1)…

AdultMaleCancer Researchmedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentMedizinDrug resistanceHematopoietic stem cell transplantationMastocytosis SystemicInternal medicinemedicineHumansTransplantation HomologousSystemic mastocytosisChildSurvival rateAgedRetrospective StudiesmastocytosisHematologybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationORIGINAL REPORTSMiddle Agedmedicine.diseaseMast cell leukemia3. Good healthSurvival RateTransplantationSettore MED/15 - MALATTIE DEL SANGUEHaematopoiesisTreatment OutcomeOncologyImmunologyCancer researchFemalebusinesstransplantation
researchProduct

Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study

2016

In the last decades, evaluation of clinically relevant thrombotic complications in patients with acute leukemia (AL) has been poorly investigated. The authors performed a multi-center study to evaluate the management of symptomatic venous thromboembolism (VTE) in adult patients with AL. The intention was to find as clinically relevant the following: symptomatic Venous Thrombosis (VT) occurred in typical (lower limbs) and atypical (cerebral, upper limbs, abdominal, etc) sites with or without pulmonary embolism (PE). Over a population of 1461 patients with AL, 22 cases of symptomatic VTE were recorded in hospitalized patients with a mean age of 54.6 years. The absolute incidence of VTE was 1.…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentPopulationLow molecular weight heparinHemorrhage030204 cardiovascular system & hematologyYoung Adult03 medical and health sciences0302 clinical medicineVenous thrombosisLow Molecular Weight HeparinHumansMedicineacute leukemiacardiovascular diseaseseducationAgedAged 80 and overVenous ThrombosisAcute leukemiaeducation.field_of_studyAcute leukemiaChemotherapyLeukemiabusiness.industrylow molecular weight heparinIncidenceIncidence (epidemiology)Disease ManagementVenous ThromboembolismHematologyMiddle Agedmedicine.diseasePulmonary embolismSurgeryVenous thrombosisOncology030220 oncology & carcinogenesisAcute DiseaseFemaleacute leukemia; low molecular weight heparin; Venous thrombosisbusinessSettore MED/15 - Malattie del SangueVenous thromboembolismLeukemia & Lymphoma
researchProduct

Monitoring of Trough Plasma Ganciclovir Levels and Peripheral Blood Cytomegalovirus (CMV)-Specific CD8 + T Cells To Predict CMV DNAemia Clearance in …

2014

ABSTRACT It is uncertain whether monitoring plasma ganciclovir (GCV) levels is useful in predicting cytomegalovirus (CMV) DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients. In this observational study, including 13 episodes of CMV DNAemia treated with intravenous (i.v.) GCV or oral valganciclovir, we showed that monitoring trough plasma GCV levels does not reliably predict response to therapy. Rather, immunological monitoring (pp65 and immediate-early [IE]-1-specific gamma interferon [IFN-γ]-producing CD8 + T cells) appeared to perform better for this purpose.

AdultMaleGanciclovirvirusesCongenital cytomegalovirus infectionCytomegalovirusCD8-Positive T-LymphocytesClinical TherapeuticsViral Matrix ProteinsInterferon-gammamedicineHumansValganciclovirCytotoxic T cellPharmacology (medical)GanciclovirMultiple myelomaPharmacologybusiness.industryLymphoma Non-HodgkinAnemia Aplasticvirus diseasesValganciclovirMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaPhosphoproteinsmedicine.diseaseTransplant RecipientsLeukemia Myeloid AcuteLeukemiaInfectious DiseasesCytomegalovirus InfectionsDNA ViralImmunologyFemaleStem cellMultiple MyelomabusinessCD8Stem Cell Transplantationmedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct

Fatal sepsis due to mycobacterium tuberculosis after allogeneic bone marrow transplantation.

2001

Mycobacterium tuberculosis is a serious, but rare infectious complication after allogeneic bone marrow transplantation. We describe a case of fatal sepsis due to Mycobacterium tuberculosis after allogeneic bone marrow transplantation for Philadelphia chromosome-positive ALL. The diagnosis was made after BAL. Although broad-spectrum antituberculous therapy was started immediately after diagnosis, blood cultures became positive for Mycobacterium tuberculosis. The patient developed severe pyrexias and finally died of multi-organ failure. Rapid progression of mycobacterial infection should be considered in patients post BMT with unexplained fever, particularly in patients from endemic areas.

AdultMaleMycobacterium tuberculosisSepsisFatal OutcomeAcute lymphocytic leukemiamedicineHumansTransplantation HomologousTuberculosisIn patientAutogenous boneBone Marrow TransplantationTransplantationbiologybusiness.industryMarrow transplantationHematologyMycobacterium tuberculosisPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseasebiology.organism_classificationmedicine.anatomical_structureImmunologyBone marrowbusinessComplicationBone marrow transplantation
researchProduct

Differential expression of specific microRNA and their targets in acute myeloid leukemia

2010

Acute myeloid leukemia (AML) the most common acute leukemia in adults is characterized by various cytogenetic and molecular abnormalities. However, the genetic etiology of the disease is not yet fully understood. MicroRNAs (miRNA) are small noncoding RNAs which regulate the expression of target mRNAs both at transcriptional and translational level. In recent years, miRNAs have been identified as a novel mechanism in gene regulation, which show variable expression during myeloid differentiation. We studied miRNA expression of leukemic blasts of 29 cases of newly diagnosed and genetically defined AML using quantitative reverse transcription polymerase chain reaction (RT-PCR) for 365 human miR…

AdultMaleNPM1Down-RegulationBiologySettore MED/15 - Malattie Del SangueYoung Adulthemic and lymphatic diseasesmicroRNAmedicineGene silencingHumansLeukemia microarray data microRNAGranulocyte Precursor CellsAgedCell ProliferationGeneticsRegulation of gene expressionAged 80 and overAcute leukemiaReverse Transcriptase Polymerase Chain ReactionGene Expression ProfilingCore Binding FactorsMyeloid leukemiaNuclear ProteinsCell DifferentiationHematologyMiddle Agedmedicine.diseaseUp-RegulationGene expression profilingGene Expression Regulation NeoplasticLeukemiaLeukemia Myeloid AcuteMicroRNAsfms-Like Tyrosine Kinase 3Case-Control StudiesMutationFemaleSettore SECS-S/01 - StatisticaNucleophosmin
researchProduct

Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia.

2013

Mutations in the nucleophosmin 1 (NPM1) gene are considered a founder event in the pathogenesis of acute myeloid leukemia (AML). To address the role of clonal evolution in relapsed NPM1-mutated (NPM1mut) AML, we applied high-resolution, genome-wide, single-nucleotide polymorphism array profiling to detect copy number alterations (CNAs) and uniparental disomies (UPDs) and performed comprehensive gene mutation screening in 53 paired bone marrow/peripheral blood samples obtained at diagnosis and relapse. At diagnosis, 15 aberrations (CNAs, n = 10; UPDs, n = 5) were identified in 13 patients (25%), whereas at relapse, 56 genomic alterations (CNAs, n = 46; UPDs, n = 10) were detected in 29 patie…

AdultMaleNPM1MyeloidImmunologyBiologyGene mutationBiochemistrySomatic evolution in cancerPolymorphism Single NucleotideDNA Methyltransferase 3AClonal EvolutionYoung AdultRecurrenceRisk FactorsmedicineHumansDNA (Cytosine-5-)-MethyltransferasesAgedChromosomes Human Pair 13Myeloid leukemiaNuclear ProteinsCell BiologyHematologyMiddle Agedmedicine.diseasePrognosisMinimal residual diseaseDNA FingerprintingLeukemiaETV6Leukemia Myeloid Acutemedicine.anatomical_structureCancer researchFemaleChromosomes Human Pair 9NucleophosminGene DeletionBlood
researchProduct

Promyelocytic leukemia (PML) gene expression is a prognostic factor in ampullary cancer patients

2008

Background: Promyelocytic leukemia (PML) tumor suppressor gene plays a key role in acute PML pathogenesis but its involvement in pathogenesis and prognosis of solid cancers has not been defined yet. Patients and methods: In all, 62 ampullary adenocarcinoma patients who underwent curative surgery between 1996 and 2005 were included. Expression analysis of PML was carried out by immunohistochemical staining and correlated with disease-free survival (DFS) and overall survival (OS). Results: In 24 tumor specimens (38.7%), PML was classified as absent, in 16 (25.8%) as focally expressed and in 22 (35.5%) as diffusely expressed. By univariate analysis, DFS was significantly influenced by patholog…

AdultMaleOncologyAmpulla of Vatermedicine.medical_specialtyPathology(PML)ampullary cancerTumor suppressor geneCommon Bile Duct NeoplasmsAdenocarcinomaPromyelocytic Leukemia ProteinsurvivalCohort StudiesPathogenesispromyelocytic leukemia gene expressionPromyelocytic leukemia proteinampulla of vater cancer; promyelocytic leukemia gene expression; prognosisInternal medicineBiomarkers TumorHumansMedicinePathologicalAgedRetrospective StudiesAged 80 and overUnivariate analysisPMLbiologybusiness.industryTumor Suppressor ProteinsNuclear Proteinsampullary cancerHematologyMiddle AgedPrognosismedicine.diseaseSurvival AnalysisGene Expression Regulation NeoplasticLeukemiaOncologyPML; ampullary cancer; survivalbiology.proteinImmunohistochemistryT-stageampulla of vater cancerFemalebusinessTranscription FactorsAnnals of Oncology
researchProduct

Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project

2014

Background: Non-Hodgkin lymphoma (NHL), the most common hematologic malignancy, consists of numerous subtypes. The etiology of NHL is incompletely understood, and increasing evidence suggests that risk factors may vary by NHL subtype. However, small numbers of cases have made investigation of subtype-specific risks challenging. The International Lymphoma Epidemiology Consortium therefore undertook the NHL Subtypes Project, an international collaborative effort to investigate the etiologies of NHL subtypes. This article describes in detail the project rationale and design. Methods: We pooled individual-level data from 20 case-control studies (17 471 NHL cases, 23 096 controls) from North Ame…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyAdolescentChronic lymphocytic leukemiaFollicular lymphomaNon-Hodgkin lymphoma (NHL)ArticleLymphoplasmacytic LymphomaYoung AdultRisk Factorsimmune system diseaseshemic and lymphatic diseasesInternal medicineEpidemiology of cancerPrevalencemedicineHumansAgedAged 80 and overMycosis fungoidesbusiness.industryLymphoma Non-HodgkinAustraliaWaldenstrom macroglobulinemiaGeneral MedicineMiddle Agedmedicine.diseaseNon-Hodgkin's lymphomaEuropeOncologyCase-Control StudiesEpidemiologic Research DesignNorth AmericaImmunologyInternational Lymphoma Epidemiology Consortiumhematologic malignancyFemaleMantle cell lymphomabusinessJNCI Monographs
researchProduct

Bcl-6 mutation status provides clinically valuable information in early-stage B-cell chronic lymphocytic leukemia

2004

In B-cell chronic lymphocytic leukemia (B-CLL), somatic mutation of IgVH genes defines a subgroup with favorable prognosis, whereas the absence of IgVH mutations is correlated with a worse outcome. Mutations of the BCL-6 gene are also observed in a subset of B-CLL, but the clinical significance of this molecular alteration remains uncertain. We examined the distribution of IgVH and BCL-6 gene mutations in 95 well-characterized patients with Binet stage A B-CLL, and correlated them with clinical, laboratory, cytogenetic findings and disease progression. Mutations of the BCL-6 gene were observed only in cases harboring mutated IgVH. Unexpectedly, coexistence of IgVH and BCL-6 mutations was co…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyChronic lymphocytic leukemiaImmunoglobulin Variable RegionLocus (genetics)BiologyGene mutationDisease-Free SurvivalGermline mutationProto-Oncogene ProteinsInternal medicinemedicineHumansB-cell chronic lymphocytic leukemiaClinical significanceProspective StudiesGeneAgedAged 80 and overHematologyChromosomes Human Pair 11HematologyMiddle AgedPrognosismedicine.diseaseLeukemia Lymphocytic Chronic B-CellDNA-Binding ProteinsOncologyMutationImmunologyProto-Oncogene Proteins c-bcl-6FemaleChromosome DeletionChromosomes Human Pair 17Follow-Up StudiesTranscription FactorsLeukemia
researchProduct

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylatin…

2018

Patients with primary refractory or relapsed-acute myeloid leukemia (RR-AML), particularly older adults, have dismal outcomes and limited therapy options [1]. Given the tolerability of hypomethylat...

AdultMaleOncologyCancer Researchmedicine.medical_specialtyMyeloidAdolescentendocrine system diseasesmedicine.medical_treatmentHematopoietic stem cell transplantationRisk AssessmentYoung AdultRisk Factorshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansTransplantation HomologousneoplasmsSurvival analysisAgedRetrospective StudiesAged 80 and overbusiness.industryHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyMiddle AgedPrognosismedicine.diseaseSurvival AnalysisTransplantationLeukemia Myeloid AcuteLeukemiaTreatment Outcomemedicine.anatomical_structureOncologyTolerabilityHypomethylating agentDrug Resistance Neoplasmhypomethylating agent acute myeloid leukemia.FemaleNeoplasm Recurrence LocalbusinessLeukemia & Lymphoma
researchProduct